FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113869422> ?p ?o ?g. }

• W2113869422 endingPage "87" @default.
• W2113869422 startingPage "83" @default.
• W2113869422 abstract "Background/AimsAround 15–25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA).MethodsTwo hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6–8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal.ResultsAmong 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5%) were found HCV-RNA positive by TMA. Twenty-two of them, (96%) were PCR-relapsers after therapy withdrawal, compared to only 14% of the 182 TMA negative patients (P<0.0001). This virological profile was more frequent in HCV-1 and HCV-3 infected patients and correlated with a slower virological response during therapy.ConclusionsAt the end of Peg-IFN plus ribavirin therapy, TMA is superior to PCR in identifying patients with sustained HCV-RNA clearance. Around 15–25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA). Two hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6–8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal. Among 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5%) were found HCV-RNA positive by TMA. Twenty-two of them, (96%) were PCR-relapsers after therapy withdrawal, compared to only 14% of the 182 TMA negative patients (P<0.0001). This virological profile was more frequent in HCV-1 and HCV-3 infected patients and correlated with a slower virological response during therapy. At the end of Peg-IFN plus ribavirin therapy, TMA is superior to PCR in identifying patients with sustained HCV-RNA clearance." @default.
• W2113869422 created "2016-06-24" @default.
• W2113869422 creator A5005200492 @default.
• W2113869422 creator A5013873890 @default.
• W2113869422 creator A5019459194 @default.
• W2113869422 creator A5022851801 @default.
• W2113869422 creator A5023873039 @default.
• W2113869422 creator A5053108546 @default.
• W2113869422 creator A5081333958 @default.
• W2113869422 creator A5081398105 @default.
• W2113869422 creator A5088417902 @default.
• W2113869422 date "2006-01-01" @default.
• W2113869422 modified "2023-10-12" @default.
• W2113869422 title "Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse" @default.
• W2113869422 cites W1972079436 @default.
• W2113869422 cites W1979931682 @default.
• W2113869422 cites W1992239172 @default.
• W2113869422 cites W1993974155 @default.
• W2113869422 cites W2020914906 @default.
• W2113869422 cites W2022873444 @default.
• W2113869422 cites W2027545702 @default.
• W2113869422 cites W2038982091 @default.
• W2113869422 cites W2052733669 @default.
• W2113869422 cites W2103639014 @default.
• W2113869422 cites W2112876622 @default.
• W2113869422 cites W2127685726 @default.
• W2113869422 cites W2142746239 @default.
• W2113869422 cites W2153921667 @default.
• W2113869422 cites W2160985864 @default.
• W2113869422 doi "https://doi.org/10.1016/j.jhep.2005.08.016" @default.
• W2113869422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16271794" @default.
• W2113869422 hasPublicationYear "2006" @default.
• W2113869422 type Work @default.
• W2113869422 sameAs 2113869422 @default.
• W2113869422 citedByCount "47" @default.
• W2113869422 countsByYear W21138694222013 @default.
• W2113869422 countsByYear W21138694222016 @default.
• W2113869422 countsByYear W21138694222017 @default.
• W2113869422 crossrefType "journal-article" @default.
• W2113869422 hasAuthorship W2113869422A5005200492 @default.
• W2113869422 hasAuthorship W2113869422A5013873890 @default.
• W2113869422 hasAuthorship W2113869422A5019459194 @default.
• W2113869422 hasAuthorship W2113869422A5022851801 @default.
• W2113869422 hasAuthorship W2113869422A5023873039 @default.
• W2113869422 hasAuthorship W2113869422A5053108546 @default.
• W2113869422 hasAuthorship W2113869422A5081333958 @default.
• W2113869422 hasAuthorship W2113869422A5081398105 @default.
• W2113869422 hasAuthorship W2113869422A5088417902 @default.
• W2113869422 hasBestOaLocation W21138694221 @default.
• W2113869422 hasConcept C126322002 @default.
• W2113869422 hasConcept C159047783 @default.
• W2113869422 hasConcept C203014093 @default.
• W2113869422 hasConcept C2522874641 @default.
• W2113869422 hasConcept C2776185481 @default.
• W2113869422 hasConcept C2776408679 @default.
• W2113869422 hasConcept C2776455275 @default.
• W2113869422 hasConcept C2776999253 @default.
• W2113869422 hasConcept C2780040827 @default.
• W2113869422 hasConcept C71924100 @default.
• W2113869422 hasConcept C90924648 @default.
• W2113869422 hasConceptScore W2113869422C126322002 @default.
• W2113869422 hasConceptScore W2113869422C159047783 @default.
• W2113869422 hasConceptScore W2113869422C203014093 @default.
• W2113869422 hasConceptScore W2113869422C2522874641 @default.
• W2113869422 hasConceptScore W2113869422C2776185481 @default.
• W2113869422 hasConceptScore W2113869422C2776408679 @default.
• W2113869422 hasConceptScore W2113869422C2776455275 @default.
• W2113869422 hasConceptScore W2113869422C2776999253 @default.
• W2113869422 hasConceptScore W2113869422C2780040827 @default.
• W2113869422 hasConceptScore W2113869422C71924100 @default.
• W2113869422 hasConceptScore W2113869422C90924648 @default.
• W2113869422 hasIssue "1" @default.
• W2113869422 hasLocation W21138694221 @default.
• W2113869422 hasLocation W21138694222 @default.
• W2113869422 hasOpenAccess W2113869422 @default.
• W2113869422 hasPrimaryLocation W21138694221 @default.
• W2113869422 hasRelatedWork W1911438026 @default.
• W2113869422 hasRelatedWork W1966676395 @default.
• W2113869422 hasRelatedWork W2008996336 @default.
• W2113869422 hasRelatedWork W2038839676 @default.
• W2113869422 hasRelatedWork W2063833450 @default.
• W2113869422 hasRelatedWork W2140057227 @default.
• W2113869422 hasRelatedWork W2328524562 @default.
• W2113869422 hasRelatedWork W2418448345 @default.
• W2113869422 hasRelatedWork W4244704181 @default.
• W2113869422 hasRelatedWork W47800385 @default.
• W2113869422 hasVolume "44" @default.
• W2113869422 isParatext "false" @default.
• W2113869422 isRetracted "false" @default.
• W2113869422 magId "2113869422" @default.
• W2113869422 workType "article" @default.